Media stories about Express Scripts (NASDAQ:ESRX) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Express Scripts earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.5886706950662 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:
Shares of Express Scripts (ESRX) traded up $3.75 during trading on Monday, reaching $68.16. 8,791,554 shares of the company were exchanged, compared to its average volume of 4,116,816. The stock has a market cap of $36,480.00, a price-to-earnings ratio of 9.42, a PEG ratio of 0.95 and a beta of 0.88. Express Scripts has a 1 year low of $55.80 and a 1 year high of $77.25. The company has a debt-to-equity ratio of 0.86, a current ratio of 0.73 and a quick ratio of 0.61.
Express Scripts (NASDAQ:ESRX) last issued its quarterly earnings results on Tuesday, October 24th. The company reported $1.90 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $1.90. The firm had revenue of $24.68 billion for the quarter, compared to analyst estimates of $25.68 billion. Express Scripts had a net margin of 3.64% and a return on equity of 25.46%. Express Scripts’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same period last year, the company posted $1.74 EPS. equities analysts anticipate that Express Scripts will post 7.01 EPS for the current fiscal year.
Several equities research analysts have commented on the stock. Deutsche Bank assumed coverage on shares of Express Scripts in a report on Monday. They issued a “buy” rating and a $75.00 price target on the stock. Mizuho set a $67.00 price target on shares of Express Scripts and gave the company a “hold” rating in a report on Tuesday, October 24th. Robert W. Baird reaffirmed a “hold” rating and issued a $56.00 price target on shares of Express Scripts in a report on Friday, September 1st. Morgan Stanley upped their price target on shares of Express Scripts from $52.00 to $57.00 and gave the company an “underweight” rating in a report on Thursday, August 10th. Finally, Royal Bank Of Canada assumed coverage on shares of Express Scripts in a report on Tuesday, September 19th. They issued a “sector perform” rating and a $68.00 price target on the stock. Six investment analysts have rated the stock with a sell rating, ten have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $70.67.
In other news, Director Woodrow A. Myers, Jr. sold 3,900 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $63.93, for a total transaction of $249,327.00. Following the completion of the sale, the director now owns 11,500 shares in the company, valued at approximately $735,195. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Timothy C. Wentworth purchased 8,000 shares of the business’s stock in a transaction dated Tuesday, October 31st. The shares were purchased at an average price of $61.13 per share, with a total value of $489,040.00. Following the acquisition, the chief executive officer now directly owns 98,628 shares in the company, valued at $6,029,129.64. The disclosure for this purchase can be found here. In the last quarter, insiders sold 5,121 shares of company stock valued at $325,920. 0.68% of the stock is owned by insiders.
COPYRIGHT VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Express Scripts (ESRX) Stock Price” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US and international copyright and trademark laws. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2017/12/04/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-express-scripts-esrx-stock-price.html.
Express Scripts Company Profile
Express Scripts, Inc is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM).
Receive News & Ratings for Express Scripts Holding Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts Holding Company and related companies with MarketBeat.com's FREE daily email newsletter.